BioLineRx shares rise 4% on first patient dosed in cancer trial
BioLineRx shares rise 4% on first patient dosed in cancer trial
BioLineRx shares rise 4% on first patient dosed in cancer trial
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.